Latest News and Press Releases

SAN RAFAEL, Calif., May 14, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Dan Spiegelman, Chief Financial Officer at BioMarin, will present a company update...

SAN RAFAEL, Calif., May 2, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Dan Maher, Senior Vice President of Product Development at BioMarin, will present a...

Total Revenue Continues Steady Growth of 10 Percent; Progress on All Aspects of the Business Conference Call and Webcast to Be Held Today at 5:00 p.m. ET Financial Highlights ($ in millions,...

SAN RAFAEL, Calif., April 24, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the submission of a Marketing Authorization Application (MAA) to the European...

SAN RAFAEL, Calif., April 18, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on April 15, 2013, the compensation committee of BioMarin's board of directors...

SAN RAFAEL, Calif., April 4, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin, will host a...

SAN RAFAEL, Calif., April 1, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has submitted a Clinical Trial Application (CTA) with the Medicines and...

SAN RAFAEL, Calif., April 1, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug...

SAN RAFAEL, Calif., March 25, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that an additional six holders of its 1.875% Convertible Senior Subordinated Notes due...

BMN-701 Meaningfully Improves Respiratory Endpoints Phase 2/3 Switch Study Expected to Begin by December 2013 Conference Call and Webcast to Be Held Today at 5:00 p.m. ET SAN RAFAEL, Calif.,...